AlloVir (ALVR) Competitors $0.89 -0.07 (-7.31%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALVR vs. BLUE, ATRA, EDIT, SAGE, CCCC, TSHA, ORGO, MGTX, TKNO, and BMEAShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include bluebird bio (BLUE), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), Sage Therapeutics (SAGE), C4 Therapeutics (CCCC), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), MeiraGTx (MGTX), Alpha Teknova (TKNO), and Biomea Fusion (BMEA). These companies are all part of the "medical" sector. AlloVir vs. bluebird bio Atara Biotherapeutics Editas Medicine Sage Therapeutics C4 Therapeutics Taysha Gene Therapies Organogenesis MeiraGTx Alpha Teknova Biomea Fusion bluebird bio (NASDAQ:BLUE) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment. Does the MarketBeat Community prefer BLUE or ALVR? bluebird bio received 1011 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 71.39% of users gave bluebird bio an outperform vote while only 57.45% of users gave AlloVir an outperform vote. CompanyUnderperformOutperformbluebird bioOutperform Votes103871.39% Underperform Votes41628.61% AlloVirOutperform Votes2757.45% Underperform Votes2042.55% Which has higher earnings & valuation, BLUE or ALVR? AlloVir has lower revenue, but higher earnings than bluebird bio. AlloVir is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobluebird bio$29.50M3.04-$211.91M-$2.22-0.21AlloVirN/AN/A-$190.42M-$1.23-0.72 Which has more risk & volatility, BLUE or ALVR? bluebird bio has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Does the media prefer BLUE or ALVR? In the previous week, bluebird bio had 1 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for bluebird bio and 2 mentions for AlloVir. AlloVir's average media sentiment score of 0.87 beat bluebird bio's score of 0.68 indicating that AlloVir is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bluebird bio 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AlloVir 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in BLUE or ALVR? 87.4% of bluebird bio shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 1.4% of bluebird bio shares are held by company insiders. Comparatively, 33.9% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is BLUE or ALVR more profitable? AlloVir has a net margin of 0.00% compared to bluebird bio's net margin of -567.29%. AlloVir's return on equity of -89.62% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets bluebird bio-567.29% -207.25% -51.70% AlloVir N/A -89.62%-73.01% Do analysts prefer BLUE or ALVR? bluebird bio presently has a consensus target price of $4.63, suggesting a potential upside of 900.72%. Given bluebird bio's stronger consensus rating and higher probable upside, research analysts clearly believe bluebird bio is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bluebird bio 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25AlloVir 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Summarybluebird bio beats AlloVir on 11 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.32M$3.11B$5.11B$8.43BDividend YieldN/A1.76%7.56%4.16%P/E Ratio-0.7216.07126.1616.71Price / SalesN/A309.871,651.6576.32Price / CashN/A144.3537.4133.56Price / Book0.693.994.614.98Net Income-$190.42M-$42.25M$116.32M$224.69M7 Day Performance-0.73%-0.22%-0.96%-0.51%1 Month Performance12.92%8.24%5.36%3.32%1 Year Performance-47.20%28.29%33.86%25.51% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVir2.6845 of 5 stars$0.89-7.3%N/A-47.2%$102.32MN/A-0.72110Upcoming EarningsBLUEbluebird bio3.0077 of 5 stars$0.46-4.1%$4.63+898.6%-86.7%$94.79M$29.50M-0.21323Analyst ForecastATRAAtara Biotherapeutics2.6028 of 5 stars$8.91-7.0%$14.00+57.1%-63.9%$47.09M$8.57M-0.23165Upcoming EarningsEDITEditas Medicine4.6577 of 5 stars$2.90-4.0%$9.91+241.7%-65.3%$249.08M$78.12M-1.23230Analyst DowngradeSAGESage Therapeutics4.3101 of 5 stars$6.08-5.6%$12.89+112.0%-72.7%$393.96M$86.46M-1.09690Earnings ReportGap DownCCCCC4 Therapeutics1.9698 of 5 stars$5.33-3.6%$10.50+97.0%+313.5%$383.44M$20.76M-2.81150Earnings ReportTSHATaysha Gene Therapies1.3753 of 5 stars$1.69-9.6%$6.38+277.2%-46.0%$383.24M$15.45M-8.45180Gap UpORGOOrganogenesis4.0314 of 5 stars$2.77-4.2%$4.88+76.0%+26.2%$383.14M$433.14M-21.31950Upcoming EarningsMGTXMeiraGTx4.4404 of 5 stars$5.54-5.8%$22.50+306.1%+12.5%$381.61M$14.02M-3.96300Upcoming EarningsTKNOAlpha Teknova1.0088 of 5 stars$6.80-4.4%$5.00-26.5%+249.5%$378.98M$36.68M-7.31240Upcoming EarningsBMEABiomea Fusion3.7646 of 5 stars$9.37-9.4%$30.50+225.5%-12.4%$374.71MN/A-2.3450Earnings ReportAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies BLUE Alternatives ATRA Alternatives EDIT Alternatives SAGE Alternatives CCCC Alternatives TSHA Alternatives ORGO Alternatives MGTX Alternatives TKNO Alternatives BMEA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALVR) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALVR Stock Alerts